CenterPoint Q3 2026 slides: $4B capital boost fuels Houston growth
Read the full story at Investing.comOpen in the live monitor
Related discussion groups
No group discusses this yet. Start a discussion group and attach this story.
More news about United States of America
- Consumer Confidence Rises for First Time in Four MonthsUS consumer confidence rose in October for the first time in four months due to brighter views about the job market and business conditions. Mike McKee reports on "Bloomberg Open Interest." (Source...
- What to expect from the Fed as Warsh weighs hot inflation, oil and US midtermsThe Federal Reserve is expected to keep interest rates on hold on Wednesday, six days before the US midterm elections, but with inflation at 3.7% and oil prices still elevated, investors see anothe...
- Nasdaq-100 comes onchain as Janus Henderson and Centrifuge launch first licensed fundThe $500 billion asset manager is launching an issuer-sponsored fund on Stellar, taking a different approach from third-party stock tokens.
- キム・ジョングク、大後輩ZICOに復讐「権力ってこういうことか」【OSEN＝イム・ヘヨン記者】キム・ジョングクと秋山成勲がジコに臭豆腐を食べるよう追い込んだ。27日に放送されたSBS Plus・MBN『男の中の男の旅行...
- Nobel-békedíjat javasol a szerb diákoknak a Johns Hopkins Egyetem konfliktuskezelést oktató tanáraA szerb egyetemisták sok mindent megértettek a politika természetéről, amit lázongó nyugati társaik nem, fejti ki a Foreign Policyban Edward Joseph, aki konfliktuskezelést oktat a baltimore-i Johns...
- UPS Raises Sales Outlook Ahead of Holiday SeasonUnited Parcel Service raises its sales outlook saying it expects a strong holiday shipping season. The courier raised prices, but demand was still high for the quarter. Earnings and revenue in the...
- From $60m in alleged fraud to 250kg of gold & luxury cars: The staggering figures behind Vietnam’s Mr Pips caseOver US$60 million in alleged investor losses, 250kg of gold, dozens of luxury cars, and more than 100 properties are among the staggering figures emerging from Vietnam's Mr Pips fraud case, as 188...
- Novartis tem despesas de US$ 2,2 bilhões após fracassos em testes clínicosA Novartis registrou cerca de US$ 2,2 bilhões (R$ 11,88 bilhões) em despesas relacionadas a dois medicamentos que fracassaram em estudos de fase avançada no mês passado, mesmo tendo elevado suas pr...